Update information
October 2018: The recommendations and section 2 were updated because the marketing authorisation for romiplostim now includes people who have not had a splenectomy.
May 2014: The recommendation wording has been updated in line with NICE's existing wording conventions and the wording used in NICE technology appraisal guidance 293: Eltrombopag for treating chronic immune thrombocytopenia (review of technology appraisal 205).
Minor changes since publication
January 2023: The title of this guidance was updated and the term 'immune (idiopathic) thrombocytopenic purpura' was changed to 'immune thrombocytopenia' throughout.
ISBN: 978-1-4731-3151-4